Company / Capital Expenditures
Tandem Diabetes Care Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$19.9M
FY2025
5-year range
$19.2M / $27.4M
FY2021-FY2025
Trend
+3.7%
vs FY2024
Sector context
#103 of 151
Health Care
What the data says
At $20M, Tandem Diabetes Care's capital expenditures ranks #103 of 151 in the Health Care sector. Capital Expenditures returned to growth in FY2025 after 2 years of decline, reaching $20M.
Based on SEC 10-K filings.
$20M in FY2025 with a 5-year CAGR of +46.2%.
Declined from $27M to $20M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -10.0%
- 5-Year CAGR
- +46.2%
- 10-Year CAGR
- -
Sector benchmark
#103 of 151 in Health CareTop 68% of 151This company $19.9M Sector average $271.7M
▼
-92.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +46.2%, indicating consistent growth.
- In FY2025, capital expenditures increased 3.7% year-over-year.
- Ranks #103 out of 151 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $19.9M | +3.7% |
| FY2024 | $19.2M | -28.3% |
| FY2023 | $26.8M | -2.2% |
| FY2022 | $27.4M | +40.3% |
| FY2021 | $19.5M | +554.4% |
| FY2020 | $3.0M | -47.8% |
| FY2019 | $5.7M | -36.0% |
| FY2018 | $8.9M | +54.9% |
| FY2017 | $5.8M | -35.5% |
| FY2016 | $8.9M | +54.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026